Clinical Trial

PSMA-RLT in Biochemically Recurrent PCa

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 13, 2024 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
Prospective single-center one-arm phase II study in patients with prostate cancer and confirmed biochemical recurrence (BCR) with PSA of ≥ 0.2 ng/ml after radical prostatectomy (RP) or PSA \> nadir + 2ng/ml after radiotherapy (RT) but not radio-morphological local recurrence after primary therapy with curative intent receive systemic therapy with only 2 cycles of highly standardized (3 GBq in first cycle and 6 GBq in the second cycle) PSMA-RLT at 6-week intervals.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-21.
Status change: Not Yet Recruiting → Recruiting 2024-02-10
Trial Details
NCT Number NCT06220188
Lead Sponsor Medical University of Vienna
Conditions Prostate Cancer Recurrent
Enrollment 20 participants
Start Date 2024-01-15
Primary Completion 2026-06 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2024-02-13